Missouri is currently home to 1894 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
NCT03930953
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Local Institution - 104, Saint Louis, Missouri
Conditions: Lymphoma, Non-Hodgkin
Register for Updates
Role of KATP Channel Loss in Type 2 Diabetes
NCT06830096
Recruiting
Insulin is a hormone that is made by β-cells in the pancreas and when released into the bloodstream helps control blood sugar levels. Insulin release is regulated by electrical activity in the β-cell which is generated by the ATP-sensitive potassium (KATP) channel. While reduced KATP activity is associated with increased insulin secretion, animals lacking KATP exhibit reduced secretion. This crossover from hypersecretion to undersecretion with KATP loss mirrors insulin secretion during type 2 di... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/17/2025
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Obesity and Type 2 Diabetes
Register for Updates
Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes
NCT06503809
Recruiting
Despite strong evidence that tight control of blood sugar reduces the risk of diabetes complications, most people with type 1 diabetes do not achieve recommended blood sugar targets. This randomized controlled trial will test whether a very-low- carbohydrate ketogenic diet can effectively and safely improve blood sugar control in adults with type 1 diabetes.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
NCT05471908
Recruiting
Compare the effectiveness of automatic vs as-needed (PRN) post-hospitalization follow-up for children who are hospitalized for common infections.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
02/17/2025
Locations: St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: Pneumonia, Urinary Tract Infections, Soft Tissue Infections, Gastroenteritis
Register for Updates
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
NCT05030441
Recruiting
This is an open-label, multicenter study exploring the efficacy of ivosidenib in patients with clonal cytopenia of undetermined significance (CCUS) with mutations in IDH1. The purpose is to establish proof of principle that ivosidenib is well-tolerated and potentially efficacious in improving blood count abnormalities in these patients. The study will also be offered in a decentralized, remote structure to patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Clonal Cytopenia of Undetermined Significance
Register for Updates
The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation
NCT04494295
Recruiting
This registry will study the use of the Aurora® Surgiscope to provide surgical access and visualization in minimally invasive removal of hematoma in the brain. Many methods of hematoma removal are available and will be based on surgeon preference. The impact of patient selection and time to surgery from last known well time will be explored.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: University of Missouri, Columbia, Missouri
Conditions: Supratentorial Hemorrhage
Register for Updates
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder (PALISADE-3)
NCT06358651
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/14/2025
Locations: Vistagen Clinical Site, St. Charles, Missouri
Conditions: Social Anxiety Disorder
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682
Recruiting
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Saint Francis Medical Center, Cape Girardeau, Missouri
Conditions: Lung Non-Small Cell Carcinoma
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: Saint Francis Medical Center, Cape Girardeau, Missouri
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Study of Oral MRT-2359 in Selected Cancer Patients
NCT05546268
Recruiting
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cell lymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular glue degrader MRT-2359 to determine safety, tolerability, maximum tolerated dose (MTD) and/or recommended Phase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: NSCLC, SCLC, DLBCL, NSCLC With High or Low L-MYC or N-MYC Expression, High Grade Neuroendocrine Cancer, L-MYC and N-MYC Amplified Solid Tumors, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
Register for Updates
Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation
NCT06812429
Recruiting
The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Inflammation
Register for Updates
Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
NCT06538181
Recruiting
VEXAS (vacuoles, E1 ubiqutin-activating enzyme, X-linked, autoinflammatory, somatic syndrome) is a recently described disorder with severe hematologic and rheumatologic manifestations caused by somatic variants in the ubiquitin- activating enzyme gene, UBA1, that is acquired in hematopoietic progenitor cells. Patients are often debilitated by autoinflammatory symptoms and there is currently no standard of care available. There is a clinically unmet need for better therapies in VEXAS Syndrome. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome, VEXAS, Vexas Syndrome
Register for Updates